Payment overview · 2025
General Payments
$560.91
30 reported records · 13 companies
Healthcare provider profile · identity verified
Benjamin Kumor, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · DUBUQUE, IA · NPI 1043445141
Verified facts
What the public records show
CMS Open Payments records show Benjamin Kumor, M.D. received $560.91 in general payments during 2025 across 30 reported records.
PFIZER INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.75 | 20.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.89 | 14.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.70 | 13.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.20 | 10.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.66 | 9.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.47 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.32 | 6.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.35 | 4.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.13 | 3.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.16 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.02 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.91 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.35 | 2.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.91 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $113.75 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.75 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.70 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $74.70 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.35 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
197 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 790 | 213 |
| Omeprazole | Omeprazole | 596 | 171 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 563 | 153 |
| Losartan Potassium | Losartan Potassium | 457 | 127 |
| Lisinopril | Lisinopril | 445 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 80 |
| Furosemide | Furosemide | 358 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 83 |
| Tramadol Hcl | Tramadol Hcl | 311 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 297 | 52 |
| Eliquis | Apixaban | 267 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 65 |
| Metformin Hcl Er | Metformin Hcl | 266 | 74 |
| Alprazolam | Alprazolam | 258 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 60 |
| Potassium Chloride | Potassium Chloride | 226 | 58 |
| Myrbetriq | Mirabegron | 197 | 18 |
| Warfarin Sodium | Warfarin Sodium | 197 | 35 |
| Simvastatin | Simvastatin | 195 | 55 |
| Gabapentin | Gabapentin | 178 | 49 |
| Lorazepam | Lorazepam | 175 | 26 |
| Spironolactone | Spironolactone | 170 | 38 |
| Carvedilol | Carvedilol | 168 | 40 |
| Allopurinol | Allopurinol | 166 | 41 |
| Atenolol | Atenolol | 157 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 39 |
| Trazodone Hcl | Trazodone Hcl | 154 | 31 |
| Jardiance | Empagliflozin | 151 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 34 |
| Famotidine | Famotidine | 131 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 42 |
| Metformin Hcl | Metformin Hcl | 123 | 32 |
| Xarelto | Rivaroxaban | 121 | 25 |
| Glimepiride | Glimepiride | 116 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 25 |
| Montelukast Sodium | Montelukast Sodium | 107 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 26 |
| Alendronate Sodium | Alendronate Sodium | 96 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 27 |
| Clonazepam | Clonazepam | 82 | 13 |
| Bupropion Xl | Bupropion Hcl | 80 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 22 |
| Cephalexin | Cephalexin | 78 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 11 |
| Meloxicam | Meloxicam | 70 | 20 |
| Pregabalin | Pregabalin | 69 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 13 |
| Celecoxib | Celecoxib | 62 | 25 |
| Prednisone | Prednisone | 62 | 33 |
| Farxiga | Dapagliflozin Propanediol | 58 | 14 |
| Ezetimibe | Ezetimibe | 57 | 18 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Sucralfate | Sucralfate | 54 | 16 |
| Baclofen | Baclofen | 53 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 51 | 13 |
| Ozempic | Semaglutide | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 13 |
| Enalapril Maleate | Enalapril Maleate | 48 | 12 |
| Mirtazapine | Mirtazapine | 48 | 12 |
| Benazepril Hcl | Benazepril Hcl | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 29 |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 27 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 16 |
| Valsartan | Valsartan | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Nystop | Nystatin | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Fiasp | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Invokana | Canagliflozin | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 11 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Keppra | Levetiracetam | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.91 · 30 records | PFIZER INC. | AIRSUPRA, Cologuard Collection Kit, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error